Edition:
United States

Pharma Mar SA (PHMR.MC)

PHMR.MC on Madrid SE C.A.T.S.

1.25EUR
16 Oct 2018
Change (% chg)

€-0.02 (-1.66%)
Prev Close
€1.27
Open
€1.29
Day's High
€1.29
Day's Low
€1.07
Volume
2,268,289
Avg. Vol
596,114
52-wk High
€3.40
52-wk Low
€1.07

Latest Key Developments (Source: Significant Developments)

Pharma Mar Requests EU Court To Annul Refusal Of Authorization For Aplidin
Tuesday, 2 Oct 2018 02:14am EDT 

Oct 2 (Reuters) - Pharma Mar SA ::APPLIES TO EUROPEAN UNION REQUESTING ANNULMENT REFUSAL OF MARKETING AUTHORIZATION FOR APLIDIN.  Full Article

AkzoNobel Acquires Xylazel in Spain
Thursday, 20 Sep 2018 08:39am EDT 

Sept 20 (Reuters) - AKZO NOBEL NV ::REG-AKZONOBEL LEADING IN DECORATIVE PAINTS AND WOODCARE IN SPAIN WITH THE ACQUISITION OF XYLAZEL S.A..ACQUIRED XYLAZEL S.A. (XYLAZEL), A 100% SUBSIDIARY OF PHARMA MAR S.A. (PHM)..XYLAZEL HAS ABOUT 100 EMPLOYEES; REVENUE FOR 2017 TOTALED APPROXIMATELY EUR 20 MILLION..  Full Article

Pharma Mar Sells Xylazel To Akzo Nobel Coatings For 21.8 Mln Euros
Thursday, 20 Sep 2018 08:14am EDT 

Sept 20 (Reuters) - Pharma Mar SA ::SAYS SELLS ITS SUBSIDIARY XYLAZEL FOR 21.8 MILLION EUROS TO AKZO NOBEL COATINGS S.L..DEAL WILL HAVE A POSITIVE IMPACT ON CONSOLIDATED INCOME STATEMENT OF GROUP OF ABOUT 10.3 MILLION EUROS.NET GAIN FROM OPERATION OF ABOUT EUR 16.6 MILLION ON PHARMA MAR’S INDIVIDUAL ACCOUNTS.  Full Article

Pharmamar Is Announcing Its Intention To Conduct A Registered Public Offering Of American Depositary Shares
Friday, 7 Sep 2018 08:30am EDT 

Sept 7 (Reuters) - Pharma Mar SA ::PHARMAMAR IS ANNOUNCING ITS INTENTION TO CONDUCT A REGISTERED PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES.  Full Article

Pharma Mar Says Chugai Terminates Licensing Agreement For Zepsyre In Japan
Friday, 27 Apr 2018 11:50am EDT 

April 27 (Reuters) - Pharma Mar SA ::SAYS SUBMITS INFORMATION REGARDING THE TERMINATION OF THE LICENSING AGREEMENT FOR JAPAN ENTERED INTO WITH CHUGAI IN RELATION TO ZEPSYRE.EFFECTIVE DATE OF TERMINATION IS IN APRIL 2019.TERMINATION DOES NOT AFFECT ANY PAYMENTS RECEIVED BY PHARMAMAR.TO INITIATE NEGOTIATIONS IN THE SHORT TERM WITH OTHER POTENTIAL LICENSEES FOR ZEPSYRE IN JAPAN.TO CONTINUE WITH PHASE I CLINICAL TRIALS INITIATED IN JAPAN IN 2017 FOR JAPANESE PATIENTS.  Full Article

Pharma Mar Q1 Net Loss Narrows To 1.3 Mln Euros YoY
Thursday, 26 Apr 2018 11:46am EDT 

April 26 (Reuters) - Pharma Mar SA ::Q1 NET LOSS 1.3 MILLION EUROS VERSUS LOSS 2.5 MILLION EUROS YEAR AGO.Q1 REVENUE 44.7 MILLION EUROS VERSUS 45.5 MILLION EUROS YEAR AGO.Q1 NEGATIVE EBITDA 888,000 EUROS VERSUS POSITIVE 70,000 EUROS YEAR AGO.  Full Article

Pharma Mar FY Net Loss Widens To 26.7 Mln Euros YoY
Wednesday, 28 Feb 2018 11:42am EST 

Feb 28 (Reuters) - PHARMA MAR SA ::FY NET LOSS 26.7 MILLION EUROS VERSUS LOSS 24.1 MILLION EUROS YEAR AGO.FY NET SALES 179.4 MILLION EUROS VERSUS 180.9 MILLION EUROS YEAR AGO.FY NEGATIVE EBITDA 7.4 MILLION EUROS.  Full Article

Pharma Mar Licenses Marine-Derived Payloads To Seattle Genetics
Wednesday, 14 Feb 2018 02:15am EST 

Feb 14 (Reuters) - PHARMA MAR SA ::LICENSES FULLY SYNTHETIC MARINE-DERIVED PAYLOADS TO SEATTLE GENETICS FOR USE IN DRUG CONJUGATES.SAYS WILL RECEIVE UPFRONT PAYMENT OF $5.0 MILLION ON SIGNING, FOLLOWED BY DEVELOPMENT MILESTONES IF A PRODUCT ENTERS CLINICAL DEVELOPMENT CONDUCTED BY SEATTLE GENETICS.IS ELIGIBLE FOR POTENTIAL APPROVAL AND SALES MILESTONES, ROYALTIES, ONCE PRODUCT GETS REGULATORY APPROVAL AND IS COMMERCIALIZED.  Full Article

Pharma Mar Requests Re-Examination Process For Aplidin From EMA
Wednesday, 3 Jan 2018 03:25am EST 

Jan 3 (Reuters) - PHARMA MAR SA ::REQUESTS PROCESS OF RE-EXAMINATION FOR APLIDIN FROM THE EUROPEAN MEDICINES AGENCY (EMA).AFTER FINALIZING RE-EXAMINATION PROCESS, EUROPEAN COMMISSION TO ISSUE FINAL VERDICT ON THE MARKETING AUTHORIZATION APPLICATION (MAA) FOR APLIDIN AROUND JUNE OR JULY.  Full Article

Pharma Mar Signs Distribution License Agreement For Aplidin In Israel
Tuesday, 2 Jan 2018 03:26am EST 

Jan 2 (Reuters) - PHARMA MAR SA ::SIGNS COMMERCIALIZATION AND DISTRIBUTION LICENSE AGREEMENT FOR APLIDIN WITH MEGAPHARM IN ISRAEL.  Full Article